- Title
- A Phase 2, Randomized, Double-Blind, Placebo- Controlled Study of Chemo-Immunotherapy Combination using Motolimod with Pegylated Liposomal Doxorubicin in Recurrent Or Persistent Ovarian Cancer: A Gynecologic Oncology Group Partners Study
- Creators
- Bradley J. Monk (Author) - Creighton UniversityM. F. Brady (Author)C. Aghajanian (Author)H. A. Lankes (Author)T. Rizack (Author)J. Leach (Author)J. M. Fowler (Author)R. Higgins (Author)P. Hanjani (Author)M. Morgan (Author)R. Edwards (Author)W. Bradley (Author)T. Kolevska (Author)P. Foukas (Author)E. M. Swisher (Author)K. S. Anderson (Author)R. Gottardo (Author)J. K. Bryan (Author)M. Newkirk (Author)K. L. Manjarrez (Author)R. S. Mannel (Author)R. M. Hershberg (Author)G. Coukos (Author)
- Additional links
- http://doi.org/10.1093/annonc/mdx049
- Publication Details
- Annals of Oncology, Vol.28(5), pp.996-1004
- Number of pages
- 996-1004
- Identifiers
- 991005932084502656
- Academic Unit
- School of Medicine; Obstetrics & Gynecology; General Medicine
- Resource Type
- Journal article
Journal article
A Phase 2, Randomized, Double-Blind, Placebo- Controlled Study of Chemo-Immunotherapy Combination using Motolimod with Pegylated Liposomal Doxorubicin in Recurrent Or Persistent Ovarian Cancer: A Gynecologic Oncology Group Partners Study
Annals of Oncology, Vol.28(5), pp.996-1004
05/01/2017
PMID: 28453702
Metrics
4 Record Views